Groupe IDI activity is divided in two areas: through its subsidiaries, EURIDI and Marco Polo Investissements, Co. is engaged in management buy-out/buy-in and growth capital investments in French small-mid caps valued between Euro7,000,000 and Euro75,000,000 also, through its subsidiary, IDI Mezzanine, is engaged in mezzanine financing. Also Co. is active in the purchase of secondary market portfolio.
  • TickerIDIP
  • ISINFR0000051393
  • ExchangeEuronext Paris
  • SectorEquity Investment Instruments
  • CountryFrance

Analysts

Christophe-Raphaël Ganet ...
  • Hana Maalej
  • Jean Sassus
  • Jeremy Garnier
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 09/19/2019

The European biotech stocks in our coverage universe have posted mixed performances since the start of the year. The pressure on share prices continued to mount as a result of fresh clinical disappointments and refinancing initiatives, notably among French biotechs. For the second part of the year, we continue to prefer Genfit (Buy, € 81 target price) for which we expect phase III results in NASH at the start of 2020, and Poxel (Buy, € 13.7 target price), which is set to benefit from ...

Hana Maalej

IDI : NAV up 3% – Good investment momentum

>NAV per share up 3% at € 61.78 - IDI this morning reported a NAV at end-June 2019 of € 61.78 per share, up 3% on the start of the year (€ 59.97 at end-2018 excluding the paid dividend of € 1.9). This performance is mainly attributable to the quality of the portfolio and the performance of the liquid assets. Solid investment momentum in the first half – investment capacity still in good shape – Dealflow well stocked - Investment momentum was b...

Christophe-Raphaël Ganet ...
  • Hana Maalej
  • Jean Sassus
  • Jeremy Garnier
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 19/09/2019

Les performances des Biotechs européennes de notre couverture ont été hétérogènes en ce début d’année. La pression boursière a continué de s’accentuer au fil de nouvelles déceptions cliniques et de refinancements notamment sur les biotechs françaises. En cette 2ème partie d’année nous continuons de privilégier Genfit (Achat, OC 81 €) dont nous attendons les résultats de phase 3 dans la NASH début 2020 ainsi que Poxel (Achat, OC 13.7 €) qui devrait bénéficier d’un newsflow dense (TIMES...

Hana Maalej

IDI : ANR en hausse de 3% – Bonne dynamique d’investissements

>ANR par action en hausse de 3% à 61.78 € - IDI publie ce matin un ANR à fin juin 2019 de 61.78 € par action, en progression de 3% depuis le début de l’année (59.97 € à fin 2018 hors dividende versé de 1.9 €). Cette performance s’explique principalement par la qualité du portefeuille et la performance des actifs liquides. Bonne dynamique d’investissement sur le semestre – Capacité d’investissement toujours solide – Dealflow bien fourni - La d...

1 director bought

A director at Idi bought 900 shares at 42.100EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members alo...

Christophe-Raphaël Ganet ...
  • Hana Maalej
  • Jean Sassus
  • Jeremy Garnier
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 09/19/2019

The European biotech stocks in our coverage universe have posted mixed performances since the start of the year. The pressure on share prices continued to mount as a result of fresh clinical disappointments and refinancing initiatives, notably among French biotechs. For the second part of the year, we continue to prefer Genfit (Buy, € 81 target price) for which we expect phase III results in NASH at the start of 2020, and Poxel (Buy, € 13.7 target price), which is set to benefit from ...

Hana Maalej

IDI : NAV up 3% – Good investment momentum

>NAV per share up 3% at € 61.78 - IDI this morning reported a NAV at end-June 2019 of € 61.78 per share, up 3% on the start of the year (€ 59.97 at end-2018 excluding the paid dividend of € 1.9). This performance is mainly attributable to the quality of the portfolio and the performance of the liquid assets. Solid investment momentum in the first half – investment capacity still in good shape – Dealflow well stocked - Investment momentum was b...

Christophe-Raphaël Ganet ...
  • Hana Maalej
  • Jean Sassus
  • Jeremy Garnier
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 19/09/2019

Les performances des Biotechs européennes de notre couverture ont été hétérogènes en ce début d’année. La pression boursière a continué de s’accentuer au fil de nouvelles déceptions cliniques et de refinancements notamment sur les biotechs françaises. En cette 2ème partie d’année nous continuons de privilégier Genfit (Achat, OC 81 €) dont nous attendons les résultats de phase 3 dans la NASH début 2020 ainsi que Poxel (Achat, OC 13.7 €) qui devrait bénéficier d’un newsflow dense (TIMES...

Hana Maalej

IDI : ANR en hausse de 3% – Bonne dynamique d’investissements

>ANR par action en hausse de 3% à 61.78 € - IDI publie ce matin un ANR à fin juin 2019 de 61.78 € par action, en progression de 3% depuis le début de l’année (59.97 € à fin 2018 hors dividende versé de 1.9 €). Cette performance s’explique principalement par la qualité du portefeuille et la performance des actifs liquides. Bonne dynamique d’investissement sur le semestre – Capacité d’investissement toujours solide – Dealflow bien fourni - La d...

Hana Maalej

IDI : NAV growth of 15.48% in 2018 – Acceleration of investment as of 2019

>NAV growth of 15.48% to € 61.87 at 31 December 2018 - IDI this morning reported its NAV at end-December 2018 which came to € 61.87 per share, an increase of 15.48% since end-2017. Shareholders' equity amounted to € 480m (+5%).At end-March, NAV per share showed a very slight increase of ~1% to € 62.56.For this performance, the company highlights the returns on investment achieved in 2018 with € 288m in proceeds from the sale of Private Equity Europe. As a re...

1 director bought

A director at Idi bought 900 shares at 42.100EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members alo...

Alain William ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Emmanuel Matot
  • Hana Maalej
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Laurence Hofmann
  • Nicolas David
  • Nicolas Thorez
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 04/26/2019

...

Alain William ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Emmanuel Matot
  • Hana Maalej
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Laurence Hofmann
  • Nicolas David
  • Nicolas Thorez
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 26/04/2019

...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Hana Maalej
  • Harold De Decker
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Léopold Authié
  • Nicolas David
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 11/09/2018

...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Hana Maalej
  • Harold De Decker
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Léopold Authié
  • Nicolas David
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 09/11/2018

...

Aurelien Sivignon ...
  • Emmanuel Matot
  • Hana Maalej
  • Harold De Decker
  • Jeremy Garnier
  • Jerôme Bodin
  • Oussema Denguir
  • Pierre Corby
  • Valentin Pernet

ODDO BHF Small & MIDCAP MORNING NEWS - 19/09/2018

...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Idi, 26 juin 2019

Notons premièrement que l'associé commandité, indéfiniment responsable des dettes sociales, est une société par actions simplifiée dont les associés ne supportent les pertes qu'à concurrence de leurs apports. La forme sociale de la SCA empêche les actionnaires commanditaires de pouvoir choisir leur premier dirigeant et porte donc atteinte à la responsabilité de celui-ci envers ces premiers. Précisons que le Gérant n'est pas directement rémunéré par IDI mais par Ancelle et Associés, ce qui n'assure pas un parfait alignement des intérêts du premier dirigeant avec ceux des associés commanditaire...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch